Peptinov is a Paris-based biotech start-up founded by Prof. Jean-François Zagury to develop innovative vaccines against non-infectious diseases (auto-immmune diseases, cancer, chronic pain).
Creation of Peptinov.
Move of Peptinov’s laboratories to Paris Biotech incubator at Cochin Hospital, Paris.
Proof of concept in mice and monkeys.
Relocation of Peptinov’s laboratories to the Cochin Biotech Business Accelerator on the campus of Cochin Hospital.
The Cochin Biotech Business Accelerator hosting Peptinov’s labs.
Laureate, FUI national grant program for the development of Peptinov’s anti-IL-1 vaccine, ensuring financing for this R&D program (performed in collaboration with industrial and academic partners) over the following 4 years.
Selection by Direction Générale de l’Armement (DGA) for a RAPID grant to develop Peptinov’s anti-TNF small molecule inhibitors, in collaboration with industrial partners, over the following 3 years.
Peptinov released an article on the safety, immunogenicity and efficacy of its anti-IL-6 active immunotherapy candidate in non-human primates in Scientific Reports (Nature Publishing Group). Article available on Scientific Reports’ website.
Hervé de Kergrohen, MD, MBA, joined Peptinov as CEO. Hervé de Kergrohen has 25 years of experience in the management and financing of innovative life science companies.
Peptinov starts the development of several anti-cancer vaccines.
Peptinov signs a collaboration agreement with a leading Animal Health corporation.